Canada markets closed

Generation Bio Co. (GBIO)

NasdaqGS - NasdaqGS Delayed Price. Currency in USD
Add to watchlist
2.7400-0.6800 (-19.88%)
At close: 04:00PM EDT
2.8000 +0.06 (+2.19%)
After hours: 07:49PM EDT

Generation Bio Co.

301 Binney Street
Cambridge, MA 02142
United States
617 655 7500

Full Time Employees174

Key Executives

NameTitlePayExercisedYear Born
Dr. Cameron Geoffrey McDonough M.D.President, CEO & Director1.01MN/A1970
Dr. Matthew Norkunas M.B.A., M.D.Chief Financial Officer668.21kN/A1978
Dr. Matthew Stanton Ph.D.Chief Scientific Officer738.21kN/A1973
Ms. Yalonda Howze J.D.Chief Legal Officer & Secretary568.81kN/A1972
Dr. Mark D. Angelino Ph.D.Co-FounderN/AN/A1973
Dr. Robert Kotin Ph.D.Co-FounderN/AN/A1956
Ms. Antoinette Paone M.B.A., M.S.Chief Operating OfficerN/AN/A1978
Ms. Jasmin TowerChief Human Resources OfficerN/AN/AN/A
Dr. Phillip Samayoa Ph.D.Chief Strategy OfficerN/AN/A1987
Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Generation Bio Co. develops non-viral genetic medicines for the treatment of rare and prevalent diseases. The company develops cell-targeted lipid nanoparticle (ctLNP) platform, a modular delivery system for nucleic acids to avoid off-target clearance by the liver and spleen that enables ctLNPs to persist in systemic circulation, which allows for highly selective and potent ligand-driven targeting to specific tissues and cell types; and novel immune-quiet DNA (iqDNA) to enable long-lasting high levels of gene expression from non-integrating episomes and avoids innate immune sensors that have long prevented DNA from use in non-viral systems. It uses its platform for developing a portfolio of programs for treating cancer, autoimmune, hematologic disorders, prioritizing sickle cell, beta-thalassemia, and hemophilia A diseases, as well as for other tissues and cell types, including retina, skeletal muscle, and central nervous system. The company was formerly known as Torus Therapeutics, Inc. and changed its name to Generation Bio Co. in November 2017. Generation Bio Co. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.

Corporate Governance

Generation Bio Co.’s ISS Governance QualityScore as of June 1, 2024 is 8. The pillar scores are Audit: 7; Board: 9; Shareholder Rights: 8; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.